D L Carlson Investment Group Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 2.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 27,357 shares of the biotechnology company’s stock after selling 575 shares during the quarter. D L Carlson Investment Group Inc. owned about 0.05% of Repligen worth $2,098,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in RGEN. Invesco Ltd. boosted its stake in Repligen by 53.0% in the second quarter. Invesco Ltd. now owns 3,088,594 shares of the biotechnology company’s stock valued at $265,465,000 after acquiring an additional 1,069,284 shares during the last quarter. BlackRock Inc. boosted its stake in Repligen by 12.4% in the second quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock valued at $545,830,000 after acquiring an additional 699,886 shares during the last quarter. Eagle Asset Management Inc. bought a new position in Repligen in the second quarter valued at approximately $40,899,000. Carillon Tower Advisers Inc. acquired a new stake in Repligen in the second quarter worth $29,287,000. Finally, Nuveen Asset Management LLC raised its holdings in Repligen by 1,207.8% in the second quarter. Nuveen Asset Management LLC now owns 362,408 shares of the biotechnology company’s stock worth $31,149,000 after purchasing an additional 334,696 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on the stock. Leerink Swann assumed coverage on shares of Repligen in a report on Tuesday, October 15th. They issued an “outperform” rating and a $100.00 target price on the stock. Svb Leerink reiterated an “outperform” rating and issued a $100.00 target price on shares of Repligen in a report on Tuesday, October 15th. ValuEngine lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Repligen in a report on Monday, August 12th. Finally, First Analysis upgraded shares of Repligen from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $107.00 to $110.00 in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Repligen currently has an average rating of “Buy” and an average price target of $105.71.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The company had revenue of $69.45 million during the quarter, compared to the consensus estimate of $66.10 million. During the same quarter last year, the firm posted $0.20 EPS. The company’s quarterly revenue was up 40.2% on a year-over-year basis. Equities analysts forecast that Repligen Co. will post 1.03 EPS for the current fiscal year.
In related news, CEO Anthony Hunt sold 3,600 shares of Repligen stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $82.89, for a total transaction of $298,404.00. Following the completion of the sale, the chief executive officer now owns 223,013 shares of the company’s stock, valued at approximately $18,485,547.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.